Over 20 years of Madopar;Mas de 20 anos de Madopar

Revista de Neurologia

Volumn 25, Issue 148, 1997, Pages 1957-1963

  Leiva, C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Benserazide; Carbidopa; Dopamine; Levadopa; Parkinson's disease; Review; The history of medicine

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; DOPAMINE; LEVODOPA; ANTIPARKINSON AGENT; BENSERAZIDE; DOPAMINE RECEPTOR STIMULATING AGENT;

CAUDATE NUCLEUS; CLINICAL PRACTICE; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG INFORMATION; HISTORY OF MEDICINE; HUMAN; PARKINSONISM; PUTAMEN; REVIEW; ARTICLE; DRUG COMBINATION; HISTORY; PARKINSON DISEASE;

ANTIPARKINSON AGENTS; BENSERAZIDE; DOPAMINE AGENTS; DRUG COMBINATIONS; HISTORY, 20TH CENTURY; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0031430902     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Koller W, ed. Handbook of Parkinson's disease. 2 ed. New York: Marcel Dekker; 1992.
2. Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. 2 ed. Baltimore: Williams & Wilkins; 1993.
3. De Ajuriaguerra J, ed. Monoamines et système nerveux central. Genève: George, Paris: Masson; 1962.
4. Hornykiewicz O. Levodopa in the 1960: Starting point in Viena. In Poewe W, Lees AJ, eds. 20 years of Madopar®. New avenues. Basel: Roche; 1994. p. 11-27.
5. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 6 ed. New York: Oxford University Press; 1991.
6. Montagu KA. Catechol compound in rat tissues and in brains of different animal. Nature 1957; 180: 244-5.
7. Weil-Malherbe H, Bone AD. Intracellular distribution os catecholamines in the brain. Nature 1957; 180: 1050-1.
8. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958; 127: 471.
9. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists. Nature 1957; 180: 1200.
10. Bertler A, Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 1959; 15: 10-1.
11. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) mi Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960; 38: 1236-9.
12. Barbeau A, Murphy CF, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science 1961; 133: 1706-7.
13. Birkmayer W, Hornykiewicz O. Der L-3-4-Dioxyphenylalanin (=DOPA)-Effekt beim Parkinson-Akinese. Wien Klin Wochernschr 1961; 73: 787-8.
14. Barbeau A, Sourkes TL, Murphy GF. Les catéholamines dan la maladie de Parkinson. In De Ajuriaguerra J, ed. Monoamines et système nerveux central. Genève: George, Paris: Masson; 1962. p. 247-62.
15. Tolosa E. Levodopa arrives in New York: The work of George Cotzias. In Poewe W, Lees AJ, eds. 20 years of Madopar®. New avenues. Basel: Roche; 1994. p. 29-42.
16. Bertler A, Rosengren E. Possible role of brain dopamine. Pharmacol Rev 1966; 18: 769-73.
17. Cotzias GC, van Woert MH, Schiffer L. Aromatic amino acids and modification of parkinsonism. N Eng J Med 1967; 276: 374-9.
18. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: Chronic treatment with L-Dopa. N Eng J Med 1969; 280: 337-45.
19. Gimeno A. Parkinson y parkinsonismos. Madrid: Roche; 1981.
20. Lee JE, Sweet RD, McDowell FH. Treatment os parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Intern Med 1971; 75: 703-8.
21. Woolen GF. Pharmacokinetics of levodopa. In Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths; 1987. p. 231-48.
22. Pletscher A. From levodopa to Madopar®. In Poewe W, Lees AJ, eds. 20 years of Madopar®. New avenues. Basel: Roche; 1994. p. 43-51.
23. Burkard WP, Gey KF, Pletscher A. A new inhibitor od decarboxilase of aromatic amino acids. Experientia 1967; 18: 411.
24. Birkmayer W, Mentasti M. Weitere experimentalle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson und Chorea-Syndrom). Arch Psychiatr und Zschr Ges Neurol 1967; 210: 29-35.
25. Bartholini G, Burkard WP, Pletscher A, Bates HM. Increase of cerebral catecholamines caused by 3,4-dihydroxiphenylalanine after inhibition of peripheral decarboxylase. Nature 1967; 215: 852-3.
26. Constantinidis J, Bartholini G, Tissot R, Pletscher A. Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain. Experientia 1968; 24: 130-1.
27. MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, Blackburn NA. Comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 220-3.
28. Chouza C, Aljanati R, Caamano JL et al. Long-term treatment with Madopar HBS in parkinsonians with fluctuations. Adv Neurol 1990; 53: 519-26.
29. Fornadi F, Milani F, Werner M. Madopar Dispersible in the treatment of advanced Parkinson's disease. Clin Neuropharmacol 1994; 17 (Suppl 3): S7-15.
30. Ghika J, Gachoud JP, Gasser U and the L-Dopa Dual-Release Study Group. Clin Neuropharmacol 1997; 20: 130-9.
31. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Fehling C, Bell MA. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Eng J Med 1972; 286: 8-14.
32. Preziosi TJ, Bianchine JR, Hsu TH, Messiha FS. L-Methyldopa hydrazine (Mk 486) and levodopa: A double-blind study in parkinsonism. Trans Am Neurol Assoc 1972; 97: 321-2.
33. Rinne UK, Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 1979; 29: 1584-9.
34. Gerlach J. Effect of CB 154 (2-bromo-alpha ergocriptine) on paralysis agitans compared with Madopar in a double-blind crossover trial. Acta Neurol Scand 1976; 53: 189-200.
35. Rinne K. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 1987; 45: 519-23.
36. Wright A, Lees AJ, Stern GM. Mesulergine and pergolide in previously untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 1987; 50: 482-4.
37. Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992; 10: 527-40.
38. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45 (Suppl 3): S13-21.
39. Rabey JM. Second generation of dopamine agonists: Pros and cons. J Neural Transm Suppl 1995; 45: 213-24.
40. Hutton JT, Koller WC, Ahlskog JE et al. Multicenter placebo controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46: 1062-5.
41. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol 1996; 39: 561-73.
42. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-42.
43. Marttila R J, Rinne UK. Disability and progression in Parkinson disease. Acta Neurol Scandinav 1977; 56: 159-69.
44. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-22.
45. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Eng J Med 1993; 328: 176-83.
46. Pollock M, Hornabrook RW. The prevalence, natural history and dementia of Parkinson's disease. Brian 1966; 89: 429-48.
47. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992; 42 (Suppl 1): S6-16.
48. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology 1985; 35: 522-6.
49. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: A baseline analysis of the DATATOP cohort. Neurology 1990; 40: 1259-534.
50. Diamond SG, Markham CH. Present mortality in Parkinson's disease: The ratio of observed to expected deaths with a method to calculate expected deaths. J Neurol Transm 1976; 38: 259-69.
51. Hoehn MM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand 1985; 71: 97-106.
52. Yahr MD. Evaluation of long-term therapy in Parkinson's disease. Mortality and therapeutic efficacy. In Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Roche; 1976. p. 435-44.
53. Sweet RD, McDowell FH. Five years treatment of Parkinson's disease with levodopa: Therapeutic results and survival of 100 patients. Ann Int Med 1975; 83: 456-63.
54. Marttila R, Rinne UK, Siirtola T, Sonninen V. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 1977; 216: 147-53.
55. Diamond SG, Markham CH, Trecokias LJ. Long-term experience with levodopa: Efficacy, progression and mortality. In Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Roche; 1976. p. 444-55.
56. Castaigne P, Rondot P, Ribadeau-Dumas JL, Cardon P. Long-term treatment of Parkinson's disease alone and in combination with a decarboxilase inhibitor. In Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Roche; 1976. p. 462-8.
57. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's disease. Ann Neurol 1978; 3: 116-8.
58. Curtis L, Lees AJ, Stern GM. Effect of levodopa on the course of Parkinson's disease. Lancet 1984; 2: 211-2.
59. Rajput AH, Offord K, Beard CM, Kurland LT. Epidemiology of parkinsonism: Incidence, classification and mortality. Ann Neurol 1984; 16: 278-82.
60. Kurtzke JF, Murphy FM. The changing patterns of death in parkinsonism. Neurology 1990; 40: 42-9.
61. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990; 40: 265-9.
62. Uitti RJ, Ahlskog JE, Maranganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmestd County project. Neurology 1993; 43: 1918-26.
63. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology. J Neurol Neurosurg Psychiatry 1995; 58: 293-9.
64. Rinne UK, Sonninen V, Siirtola T, Marttila R. Long-term responses of Parkinson's disease to levodopa therapy. J Neural Transm 1980; (Suppl 16): 149-56.
65. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multicenter study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22: 8-12.
66. Lees AJ. Levodopa substitution: The gold standard. Clin Neuropharmacol 1994; 17 (Suppl): S1-6.
67. Oertel WH, Eichhorn T. Conclusions. Clin Neuropharmacol 1994; 17 (Suppl): S51-5.
68. Lang AE. Is the symptomatic treatment of Parkinson's disease controversial. In Stern MB, ed. Beyond the Decade of the Brain. Kent: Wells Medical; 1994. p. 11-29.
69. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: Clinical aspects. In Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth; 1982. p. 96-122.
70. Fahn S. Fluctuations of disability in Parkinson's disease: Patophysiological aspects. In Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth; 1982. p. 123-45.
71. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987; 21: 370-6.
72. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms. Part I. Ann Neurol 1988; 24: 366-71.
73. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms. Part I. Ann Neurol 1988; 24: 372-8.
74. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989; 39 (Suppl 2): S11-9.
75. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459-64.
76. Poewe WH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology 1994; 44 (Suppl): S6-9.
77. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994; 44 (Suppl): S15-18.
78. Caraceni T. A case for early levodopa treatment of Parkinson's disease. Clin Neuropharmacol 1994; 3 (Suppl): S38-42.
79. Quinn NP. A case against early levodopa treatment of Parkinson's disease. Clin Neuropharmacol 1994; 17 (Suppl): S43-9.
80. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996; 71: 659-70.
81. Fahn S. Is levodopa toxic? Neurology 1996; 47 (Suppl 3): S184-95.
82. Fahn S. Adverse effects of levodopa. In Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Carnforth, England: Parthenon; 1992. p. 89-112.
83. Parkinson's disease Reserarch Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report. BMJ 1993; 307: 469-72.
84. Poewe WH, Lees AJ, Stern GM. Low-dose L-Dopa therapy in Parkinson's disease: A 6-year follow-up study. Neurology 1986; 36: 1528-30.
85. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney Multicentre Study of Parkinson's disease: A randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-10.
86. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93: 14-20.
87. Tolosa E, Hutton JT, Capildeo R. CR FIRST study: Results of a 5-year comparative trial of Sinemet® CR vs standard Sinemet® in treatment of levodopa-naive patients with Parkinson's disease. Presentado en el IV Congreso Internacional de Trastornos del Movimiento. Viena, Austria, 20 de junio, 1996.
88. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2: 73-91.
89. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41: 202-5.
90. Yokochi M, Narabayashi H, Izuka R, Nagatsu T. Juvenile parkinsonism: Some clinical, pharmacological, and neuropathological aspects. Adv Neurol 1984; 40: 407-13.
91. Van der Drift JHA. Low-dosage treatment in de novo patients with Parkinson's disease: A prospective study. Adv Neurol 1986; 45: 529-34.
92. Cederbaum JM, McDowell FH. Sixteen-year follow-up of 100 patients begun on levodopa in 1968: Emerging problems. Adv Neurol 1986; 45: 469-72.
93. Agyd Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F. The efficacy of levodopa treatment declines in the course of Parkinson's disease: Do nondopaminergic lesions play a role? Adv Neurol 1990; 53: 83-100.
94. Golbe LI, Sage JI. Medical treatment of Parkinson's disease. In Kurlan R, ed. Treatment of movement disorders. Philadelphia: Lippincott; 1995. p. 1-56.
95. Hauser RA, Freeman TB, Olanow CW. Surgical therapies for Parkinson's disease. In Kurlan R, ed. Treatment of movement disorders. Philadelphia: Lippincott; 1995. p. 57-93.
96. LeWitt PA. Treatment strategies for extension of levodopa effect. Neurol Clin 1992; 10: 511-26.
97. Tolosa E, Valldeoriola F. Mid-stage parkinsonism with mild motor fluctuations. Clin Neuropharmacol 1994; 17 (Suppl): S19-31.
98. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994; 17 (Suppl): S32-44.
99. Pfeiffer R. Optimization of levodopa therapy. Neurology 1992, 42 (Suppl 1): S39-43.
100. Koller WC, Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology 1994; 44 (Suppl 6): S23-8.
101. Mizuno Y, Kondo T, Mori H. Various aspects of motor fluctuations and their manegement in Parkinson's disease. Neurology 1994; 44 (Suppl 6): S29-34.
102. Tolosa E, Vallderiola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44 (Suppl 6): S35-44.
103. Olanow CW. The role of surgery in the treatment of Parkinson's disease. In Stern MB, ed. Beyond the Decade of the Brain. Kent: Wells Medical; 1994. p. 157-75.
104. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997; 20: 95-115.
105. Goldstein M, Liebermann A. The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology 1992; 42 (Suppl 4): S8-12.
106. Da Prada M, Borgulya J, Napolitano A. Zürcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-Adenosyl-L-Methionine: Sparing effect. Clin Neuropharmacol 1994; 17 (Suppl): S26-37.
107. Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor in Parkinson's disease. Clin Neuropharmacol 1995; 18: 258-65.
108. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Moradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993; 43: 2685-8.
109. Kurth MC, Adler CH, Saint-Hilaire MH, et al. Tolcapone improves motor function and reduces levodopa requirements in patients with Parkinson's disease (PD) experiencing end-of-dose fluctuations. Neurology 1995; 45 (Suppl 4): S275.
110. Myllylä VV and the Tolcapone in PD Study Group I (TIPS). Clinical efficacy of tolcapone in L-Dopa treated parkinsonian patients with 'wearing off' phenomenon: a multicenter double-blind study. Neurology 1995; 45 (Suppl 4): S276.
111. Davis TL, Charles PD, Saint-Hilaire MH, et al. An open label trial of tolcapone in Parkinson's disease. Mov Disord 1996 (Suppl 1): 160 (abstract).